Carna Biosciences (4572) Earnings: Net Sales Increase by +59.8% YoY, Operating Loss Reported at 954 Million Yen

Carna Biosciences (4572) has released its financial results, reporting net sales of 410 million yen, representing a year-on-year increase of +59.8%. However, the company posted an operating loss of 954 million yen, an ordinary loss of 1,005 million yen, and a net loss attributable to owners of the parent of 1,039 million yen. Earnings per share (EPS) stood at -53.13 yen.

From a financial structure and valuation perspective, the equity ratio is -8.1% with retained earnings at -2.49 billion yen, highlighting challenges in capital stability. Interest-bearing debt stands at 1.74 billion yen. Regarding profitability and efficiency metrics, the Return on Equity (ROE) is recorded at 195.46%, while the Return on Assets (ROA) is -23.18%. Market participants will closely monitor future earnings recovery and balance sheet improvements.